Citation Impact
Citing Papers
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
2007 StandoutNobel
Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein
2000 StandoutNobel
Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition
2006 StandoutNobel
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
1998
Recombinant Adenovirus Expressing Von Hippel-Lindau-Mediated Cell Cycle Arrest Is Associated with the Induction of Cyclin-Dependent Kinase Inhibitor p27Kip1
1998
mTOR Signaling in Growth Control and Disease
2012 Standout
Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes
1999
Non-viral gene delivery in skeletal muscle: a protein factory
2003
Activation of Atypical Protein Kinase C ζ by Caspase Processing and Degradation by the Ubiquitin-Proteasome System
2000 StandoutNobel
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
2004 StandoutNobel
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters
2002
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Hypoxia and Inflammation
2011 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Renal-Cell Carcinoma
1996 Standout
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
Molecular Genetic Analysis of the von Hippel-Lindau Disease Tumor Suppressor Gene in Familial and Sporadic Cerebellar Hemangioblastomas
1997
The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing
2003 StandoutNobel
Gene Therapy Progress and Prospects: Nonviral vectors
2002
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
von Hippel-Lindau Disease
1997 StandoutNobel
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
2021
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease
2001
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
2002 StandoutNobel
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
1999 StandoutNobel
Differential Function of the Prolyl Hydroxylases PHD1, PHD2, and PHD3 in the Regulation of Hypoxia-inducible Factor
2004 StandoutNobel
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
1998 StandoutNobel
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Dendrimer biocompatibility and toxicity
2005
The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C
2001
HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation
2003 Standout
Renal-Cell Carcinoma
2005
Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer
2000
The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways
1997
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 Standout
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
2003 Standout
Mechanisms of angiogenesis
1997 StandoutNature
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
2005
Selection of Mutant CHO Cells with Constitutive Activation of the HIF System and Inactivation of the von Hippel-Lindau Tumor Suppressor
2001 StandoutNobel
The PI3K Pathway in Human Disease
2017 Standout
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity
2001 StandoutNobel
The VHL tumour-suppressor gene paradigm
1998 StandoutNobel
Activation of Sp1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor Transcription Requires Specific Interaction with Protein Kinase C ζ
1998
Inactivation of the von Hippel–Lindau ( VHL ) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL ‐independent pathway in clear cell renal tumourigenesis
1998
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
1996
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
von Hippel-Lindau Disease
2006 StandoutNobel
HIF hydroxylation and the mammalian oxygen-sensing pathway
2003 StandoutNobel
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
The effect of particle design on cellular internalization pathways
2008 Standout
The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion.
2001
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
1998 StandoutNobel
Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity
2005
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles
2004 StandoutNobel
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel
Works of T Kishida being referenced
Highly efficient gene transfer into murine liver achieved by intravenous administration of naked Epstein–Barr virus (EBV)-based plasmid vectors
2001
Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo
2003
In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice
2001
Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice
2006
Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene.
1995